A systematic review of full economic evaluations of robotic-assisted surgery in thoracic and abdominopelvic procedures
- PMID: 37843673
- PMCID: PMC10678817
- DOI: 10.1007/s11701-023-01731-7
A systematic review of full economic evaluations of robotic-assisted surgery in thoracic and abdominopelvic procedures
Abstract
This study aims to conduct a systematic review of full economic analyses of robotic-assisted surgery (RAS) in adults' thoracic and abdominopelvic indications. Authors used Medline, EMBASE, and PubMed to conduct a systematic review following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Fully published economic articles in English were included. Methodology and reporting quality were assessed using standardized tools. Majority of studies (28/33) were on oncology procedures. Radical prostatectomy was the most reported procedure (16/33). Twenty-eight studies used quality-adjusted life years, and five used complication rates as outcomes. Nine used primary and 24 studies used secondary data. All studies used modeling. In 81% of studies (27/33), RAS was cost-effective or potentially cost-effective compared to comparator procedures, including radical prostatectomy, nephrectomy, and cystectomy. Societal perspective, longer-term time-horizon, and larger volumes favored RAS. Cost-drivers were length of stay and equipment cost. From societal and payer perspectives, robotic-assisted surgery is a cost-effective strategy for thoracic and abdominopelvic procedures.Clinical trial registration This study is a systematic review with no intervention, not a clinical trial.
Keywords: Cost-effectiveness analysis; Cost-utility analysis; Robotic-assisted surgery; Systematic review; Thoracic and abdominopelvic.
© 2023. The Author(s).
Conflict of interest statement
Hamid Sadri and Padina Pezeshki are employees of Medtronic, the manufacturer of surgical robots. Bobby Shayegan have received research fund from Bayer, Janssen, Pfizer and attend advisory boards/consultancy at Bayer, Janssen, Astellas, Novartis, Pfizer, Astra Zeneca, Intuitive Surgical, Knight. Michael Fung-Kee-Fung did not declare any conflict of interest. Pierre Y. Garneau has been speaker for Novo Nordisk and received educational grant from Medtronic. The authors declare that this work has not been published previously, that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.
Figures
References
-
- Vecchio R, MacFayden BV, Palazzo F. History of laparoscopic surgery. Panminerva Med. 2000;42:87–90. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources